Onco Wiki / Біомаркер

CD20 expression by immunohistochemistry

Детермінований перегляд YAML-сутності з джерельної бази. Клінічний авторитет лишається за вказаними source ID та статусом клінічного sign-off.

Дані про біомаркер

Нотатки

CD20+ status is обов'язковий for any anti-CD20 моноклональне антитіло терапія (ритуксимаб, обінутузумаб). найбільш B-cell lymphomas are CD20+; рідкісний exceptions (some HHV-8+ neoplasms, certain plasmablastic lymphomas) may be CD20- and require alternative схеми. Status can change post-ритуксимаб — re-біопсія on рецидив.

Де використовується

Algorithms

• ALGO-PMBCL-2L - ALGO-PMBCL-2L
• ALGO-PTLD-1L - ALGO-PTLD-1L

Handbook Chapters

• HB-DLBCL-1L - Diffuse large B-cell lymphoma: first-line reasoning

Indications

• IND-BURKITT-1L-CODOXM-IVAC - IND-BURKITT-1L-CODOXM-IVAC
• IND-BURKITT-1L-DAEPOCHR - IND-BURKITT-1L-DAEPOCHR
• IND-BURKITT-1L-HYPERCVAD-R - IND-BURKITT-1L-HYPERCVAD-R
• IND-BURKITT-2L-RDHAP-ASCT - IND-BURKITT-2L-RDHAP-ASCT
• IND-BURKITT-2L-RICE-ASCT - IND-BURKITT-2L-RICE-ASCT
• IND-CHL-PREGNANCY-MOD-ABVD - IND-CHL-PREGNANCY-MOD-ABVD
• IND-CLL-3L-LISOCEL - IND-CLL-3L-LISOCEL
• IND-DLBCL-1L-POLA-R-CHP - IND-DLBCL-1L-POLA-R-CHP
• IND-DLBCL-1L-RCHOP - IND-DLBCL-1L-RCHOP
• IND-DLBCL-1L-RCHOP-ISRT-EARLY - IND-DLBCL-1L-RCHOP-ISRT-EARLY
• IND-DLBCL-2L-LISOCEL - IND-DLBCL-2L-LISOCEL
• IND-DLBCL-2L-POLA-R-BENDAMUSTINE - IND-DLBCL-2L-POLA-R-BENDAMUSTINE
• IND-DLBCL-3L-AXICEL-CART - IND-DLBCL-3L-AXICEL-CART
• IND-DLBCL-3L-EPCORITAMAB - IND-DLBCL-3L-EPCORITAMAB
• IND-DLBCL-3L-GLOFITAMAB - IND-DLBCL-3L-GLOFITAMAB
• IND-DLBCL-3L-LISO-CEL-CART - IND-DLBCL-3L-LISO-CEL-CART
• IND-DLBCL-3L-LONCASTUXIMAB - IND-DLBCL-3L-LONCASTUXIMAB
• IND-DLBCL-RENAL-FAILURE-MOD-RCHOP - IND-DLBCL-RENAL-FAILURE-MOD-RCHOP
• IND-FL-1L-BR - IND-FL-1L-BR
• IND-FL-1L-RCHOP-AGGRESSIVE - IND-FL-1L-RCHOP-AGGRESSIVE
• IND-FL-1L-WATCH - IND-FL-1L-WATCH
• IND-FL-3L-AXICEL-CART - IND-FL-3L-AXICEL-CART
• IND-FL-3L-MOSUNETUZUMAB - IND-FL-3L-MOSUNETUZUMAB
• IND-FL-POST-INDUCTION-RITUXIMAB-MAINTENANCE - IND-FL-POST-INDUCTION-RITUXIMAB-MAINTENANCE
• IND-HGBL-DH-1L-DAEPOCHR - IND-HGBL-DH-1L-DAEPOCHR
• IND-HGBL-DH-1L-RCHOP - IND-HGBL-DH-1L-RCHOP
• IND-HGBL-DH-2L-CART-AXICEL - IND-HGBL-DH-2L-CART-AXICEL
• IND-MCL-1L-BTKI-R - IND-MCL-1L-BTKI-R
• IND-MCL-1L-INTENSIVE - IND-MCL-1L-INTENSIVE
• IND-MCL-3L-BREXUCEL-CART - IND-MCL-3L-BREXUCEL-CART
• IND-MCL-3L-LISOCEL - IND-MCL-3L-LISOCEL
• IND-MCL-POST-INDUCTION-RITUXIMAB-MAINTENANCE - IND-MCL-POST-INDUCTION-RITUXIMAB-MAINTENANCE
• IND-NLPBL-1L-OBSERVATION-OR-RT - IND-NLPBL-1L-OBSERVATION-OR-RT
• IND-NLPBL-1L-RITUXIMAB-MONO - IND-NLPBL-1L-RITUXIMAB-MONO
• IND-NLPBL-2L-RCHOP-TRANSFORMATION - IND-NLPBL-2L-RCHOP-TRANSFORMATION
• IND-NMZL-1L-BR - IND-NMZL-1L-BR
• IND-NMZL-1L-HCV-POSITIVE - IND-NMZL-1L-HCV-POSITIVE
• IND-NMZL-1L-WATCH - IND-NMZL-1L-WATCH
• IND-NMZL-2L-BR - IND-NMZL-2L-BR
• IND-PCNSL-1L-MATRIX - IND-PCNSL-1L-MATRIX
• ... 9 ще

Questionnaires

• QUEST-BURKITT-1L-STUB - Burkitt Lymphoma — first line
• QUEST-CHL-1L-STUB - Classical Hodgkin Lymphoma — first line
• QUEST-DLBCL-NOS-1L-STUB - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified — first line
• QUEST-FL-1L-STUB - Follicular Lymphoma — first line
• QUEST-HGBL-DH-1L-STUB - High-Grade B-Cell Lymphoma, Double-Hit / Triple-Hit — first line
• QUEST-MCL-1L-STUB - Mantle Cell Lymphoma — first line
• QUEST-NLPBL-1L-STUB - Nodular Lymphocyte-Predominant B-cell Lymphoma — first line
• QUEST-NODAL-MZL-1L-STUB - Nodal Marginal Zone Lymphoma — first line
• QUEST-PCNSL-1L-STUB - Primary CNS Lymphoma — first line
• QUEST-PMBCL-1L-STUB - Primary Mediastinal Large B-Cell Lymphoma — first line
• QUEST-PTLD-1L-STUB - Post-Transplant Lymphoproliferative Disorder — first line
• QUEST-SPLENIC-MZL-1L-STUB - Splenic Marginal Zone Lymphoma — first line